Measurement of Alpha4beta2 Nicotinic Acetylcholine Receptors with [123I]5-I-A-85380 SPECT
Overview
Affiliations
Unlabelled: Nicotinic acetylcholine receptors (nAChRs) play an important role in tobacco dependence and a potential therapeutic role in neuropsychiatric disorders such as Alzheimer's disease. [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) is a new SPECT tracer that labels alpha4beta2 nAChRs. The purpose of this study was to assess the usefulness of this tracer to measure regional nAChR binding in baboon brain using both a bolus/kinetic paradigm and also a bolus plus constant infusion/equilibrium paradigm.
Methods: A pair of bolus/kinetic and bolus plus constant infusion/equilibrium studies was performed in each of 3 isoflurane-anesthetized baboons. Bolus studies were performed by intravenous injection of 191-226 MBq [123I]5-I-A-85380 and image acquisition for 289-367 min. The data were analyzed with 1- and 2-tissue compartment models. Bolus plus constant infusion/equilibrium studies were performed by a bolus injection (74-132 MBq) followed by a 468- to 495-min infusion with a bolus/infusion ratio (B/I) of 4.8-5.0 h. The distribution volumes in the thalamus were measured in these 2 paradigms. To study whether the cerebellum was appropriate as a receptor-poor region, displacement studies were done in 2 baboons using the B/I paradigm with subcutaneous injection of (-)-cytisine (0.8 and 1.0 mg/kg).
Results: The kinetics of this tracer was best described by the 1-tissue compartment model. The 2-compartment model showed poor identifiability of rate constants. The total (specific plus nondisplaceable compartments) distribution volumes (V(T)') agreed between bolus and B/I paradigms (average percentage difference in V(T)', 16.8%). (-)-Cytisine (0.8 and 1.0 mg/kg) displaced 70% and 72% of the radioactivity in the thalamus and 36% and 55% in the cerebellum, respectively, indicating that the latter was not appropriate as a receptor-poor region.
Conclusion: These results show the feasibility of quantifying alpha4beta2 nAChRs using [123I]5-I-A-85380 and support the use of V(T)' as an appropriate outcome measure.
Imaging changes in synaptic acetylcholine availability in living human subjects.
Esterlis I, Hannestad J, Bois F, Sewell R, Tyndale R, Seibyl J J Nucl Med. 2012; 54(1):78-82.
PMID: 23160789 PMC: 3703589. DOI: 10.2967/jnumed.112.111922.
Anderson S, Brunzell D PLoS One. 2012; 7(11):e48665.
PMID: 23144922 PMC: 3492489. DOI: 10.1371/journal.pone.0048665.
Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.
Saricicek A, Esterlis I, Maloney K, Mineur Y, Ruf B, Muralidharan A Am J Psychiatry. 2012; 169(8):851-9.
PMID: 22772158 PMC: 3494404. DOI: 10.1176/appi.ajp.2012.11101546.
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler.
Esterlis I, Mitsis E, Batis J, Bois F, Picciotto M, Stiklus S Int J Neuropsychopharmacol. 2010; 14(3):389-98.
PMID: 21029513 PMC: 3510008. DOI: 10.1017/S1461145710001227.
Esterlis I, Cosgrove K, Batis J, Bois F, Stiklus S, Perkins E J Nucl Med. 2010; 51(8):1226-33.
PMID: 20660383 PMC: 3707518. DOI: 10.2967/jnumed.109.072447.